INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 169 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2021. The put-call ratio across all filers is 0.81 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,082,502 | -17.8% | 78,374 | -0.1% | 0.03% | -11.4% |
| Q2 2023 | $4,967,074 | +37.5% | 78,444 | +17.6% | 0.04% | +29.6% |
| Q1 2023 | $3,612,780 | -30.7% | 66,718 | -32.2% | 0.03% | -32.5% |
| Q4 2022 | $5,211,244 | +12.1% | 98,474 | -1.5% | 0.04% | +5.3% |
| Q3 2022 | $4,650,000 | -20.5% | 99,930 | -2.4% | 0.04% | -13.6% |
| Q2 2022 | $5,846,000 | -11.4% | 102,414 | -5.0% | 0.04% | +2.3% |
| Q1 2022 | $6,599,000 | +18.3% | 107,838 | +1.2% | 0.04% | +22.9% |
| Q4 2021 | $5,577,000 | -10.6% | 106,559 | -36.3% | 0.04% | -16.7% |
| Q3 2021 | $6,237,000 | -10.1% | 167,311 | -1.6% | 0.04% | -8.7% |
| Q2 2021 | $6,939,000 | +20.1% | 169,994 | -0.2% | 0.05% | +17.9% |
| Q1 2021 | $5,779,000 | -5.3% | 170,333 | -11.2% | 0.04% | -13.3% |
| Q4 2020 | $6,101,000 | – | 191,850 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |